Effectiveness of pancreatic enzyme replacement therapy for patients with unresectable pancreatic cancer; a prospective cohort study

Effectiveness of pancreatic enzyme replacement therapy for patients with unresectable pancreatic cancer; a prospective cohort study - Effectiveness of pancreatic enzyme replacement therapy for patients with unresectable pancreatic cancer; a prospective cohort study(AOE study2)

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040392

Enrollment

Registered

2020-06-01

Start date

2020-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.previously untreated and histopathologically confirmed unresectable pancreatic cancer patients 2.provided written informed consent

Exclusion criteria

Exclusion criteria: 1.severe complication 2.disability of oral intake 3.Inflammatory bowel disease 4.ECOG scale of performance status 3-4

Design outcomes

Primary

Measure	Time frame
Serum albumin at 3 months compare with historical control	—

Secondary

Measure	Time frame
compare with historical control below 1.serum total protein at 3 months 2.HbA1c at 3 months 3.how long days patients could receive chemotherapy 4.over all survival 5.body mass index at 3 months 6.how many pancreatic enzyme drugs patients could have at 3 months	—

Countries

Japan

Contacts

Public ContactRyo Harada

Japanese Red Cross Okayama Hospital Department of Gastroenterology

oka-rcgh@okayama-med.jrc.or.jp086-222-8811

Outcome results